- authorisedTherapeutic confirmatory (Phase III)
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy
This study looks at a medicine called venglustat for children aged 2 to 11 with Gaucher disease type 3. Researchers want to find out if venglustat works as well as the standard treatment, Cerezyme, at keeping the spleen, liver, and blood healthy over one year.
Hungary · Italy · France - recruitingHuman Pharmacology (Phase I)- Other
Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants
This study is looking at a new medicine called SAR445611. It wants to see how this medicine affects the body's reaction to something that causes inflammation, like an infection. It's for healthy men aged 18 and over.
Netherlands - recruitingHuman Pharmacology (Phase I)- First administration to humans
A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS
This early-stage study is looking at a new medicine called OX118 for the very first time in people. It aims to see if it's safe and how it works in healthy volunteers, meaning people who don't have any immune system diseases.
Sweden - recruitingHuman Pharmacology (Phase I)- Other
A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants
This study looks at how a new medicine, balinatunfib, is absorbed into the blood when taken in different tablet forms and with or without food. It involves healthy adults and aims to understand the best way for the body to take in the medicine, which is being developed for immune system diseases.
Belgium - recruitingHuman Pharmacology (Phase I)- First administration to humans
First-in-human study of SAR445611 in healthy adult participants
This early-stage study is testing a new medicine called SAR445611 for the first time in healthy adult volunteers. The aim is to see how safe it is and how it works in the body, which could help people with immune system problems in the future.
Belgium - recruitingTherapeutic exploratory (Phase II)
J1A-MC-KDAF: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
This study is testing a new medicine, peresolimab, for adults with moderate to severe rheumatoid arthritis. It aims to see if the medicine can reduce arthritis symptoms, like joint pain and swelling, better than a dummy treatment.
Hungary · Spain · Italy - recruitingPHASE2
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
This study looks at a new drug, Sparsentan, for people with kidney disease called IgA Nephropathy. It aims to see if the drug is safe and helpful in protecting the kidneys, both for newly diagnosed patients and those who have had a kidney transplant.
United Kingdom - authorisedTherapeutic confirmatory (Phase III)
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Duvakitug for people with moderate to severe ulcerative colitis. It aims to see if Duvakitug can help keep symptoms in remission (controlled) and improve quality of life compared to a dummy medicine.
Slovakia · Germany · Austria - authorisedTherapeutic confirmatory (Phase III)
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
This study is looking at a new medicine called duvakitug for people with moderate to severe Crohn's disease. Researchers want to see if it helps keep the disease under control and is safe to use. It's a phase 3 study, meaning many people will take part.
Spain · Czechia · Lithuania